Selecting & Validating the Most SuitableModel System Models to Overcome Resistance & Improve ADC Efficacy & Safety

This workshop aims to dive into the strengths and limitations of various in vitro to in vivo models (PDX, syngeneic, humanized mice, organoids) for predicting ADC performance and addressing the movement toward new alternative methodologies and better understanding of PKPD dynamics to evaluate safety and efficacy.

Key Questions:

• How do we select the right animal model for each ADC programme?
• What are the best practices for translating mouse efficacy to human dose?
• How can organoids and MPS systems complement or replace animal studies?

Speakers:

Charles Dumontet

Deputy Director & Investigator

Cancer Research Centre of Lyon

Daria Galas-Filipowicz

Clinical Pharmacology & Safety Sciences Oncology Safety Postdoctoral Fellow

AstraZeneca

Diana Hudecz

Senior Scientist

SOTIO Biotech a.s.

Ezgi Wood

Associate Director QSP

Bristol Myers Squibb